Table 5 The predictive impact of a CA125 decrease after the first cycle on the efficacy
From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
| A CA125 decrease after the first cycle | YES (N = 39, 42.4%) | NO (N = 53, 57.6%) | P-valuea |
|---|---|---|---|
| Complete remission, No. (%) | 1 (2.6%) | 1 (1.9%) | P > 0.999 |
| Partial remission, No. (%) | 25 (64.1%) | 16 (30.2%) | P = 0.001 |
| Stable disease, No. (%) | 9 (23.1%) | 23 (43.4%) | P = 0.043 |
| Disease progression, No. (%) | 4 (10.3) | 13 (24.5%) | P = 0.081 |
| ORRb, (95%CI) | 26 (66.7%) | 17 (32.1%) | P = 0.001 |
| DCRc, (95%CI) | 35 (89.7%) | 40 (75.5%) | P = 0.081 |